Mario U Mondelli Selected Research

COVID-19

6/2022	Early and Polyantigenic CD4 T Cell Responses Correlate with Mild Disease in Acute COVID-19 Donors.
1/2022	Antibodies: A Double Leg Takedown Against COVID-19.
1/2022	Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients.
1/2022	The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males.
1/2021	Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study.
1/2021	Unique immunological profile in patients with COVID-19.
10/2020	The obesity paradox: Analysis from the SMAtteo COvid-19 REgistry (SMACORE) cohort.
6/2020	Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mario U Mondelli Research Topics

Disease

31	Infections 07/2022 - 08/2003
14	Chronic Hepatitis C 10/2021 - 08/2003
11	Fibrosis (Cirrhosis) 10/2021 - 04/2003
10	Neoplasms (Cancer) 07/2022 - 07/2002
8	COVID-19 06/2022 - 06/2020
6	Liver Diseases (Liver Disease) 06/2020 - 07/2002
5	Hepatocellular Carcinoma (Hepatoma) 09/2021 - 05/2004
5	Liver Neoplasms (Liver Cancer) 10/2019 - 04/2003
5	Virus Diseases (Viral Diseases) 01/2019 - 08/2003
3	Inflammation (Inflammations) 10/2021 - 04/2006
3	Hepatitis 10/2019 - 04/2003
3	Reinfection 01/2019 - 02/2009
3	Hepatitis B 01/2019 - 09/2005
3	Hepatitis C 02/2009 - 05/2003
2	Communicable Diseases (Infectious Diseases) 03/2020 - 05/2014
2	Chronic Hepatitis B 01/2019 - 09/2009
2	Cryoglobulinemia 10/2015 - 09/2011
2	Chronic Hepatitis (Chronic Active Hepatitis) 09/2004 - 05/2003
1	Bites and Stings (Sting) 07/2022
1	Cholangiocarcinoma 01/2022
1	Heart Diseases (Heart Disease) 10/2020
1	Interstitial Lung Diseases (Interstitial Lung Disease) 10/2020
1	Obesity 10/2020
1	Autoimmune Hepatitis 01/2018
1	Vasculitis (Vasculitides) 10/2015
1	Needlestick Injuries (Needlestick Injury) 01/2015
1	Poliomyelitis (Polio) 05/2014
1	Smallpox (Variola) 05/2014
1	Gallstones (Gallstone) 09/2012
1	Lymphoma (Lymphomas) 09/2011
1	Disease Progression 02/2009
1	Alcoholism (Alcohol Abuse) 01/2005
1	Fatty Liver 01/2005
1	Insulin Resistance 01/2005
1	Body Weight (Weight, Body) 09/2004

Drug/Important Bio-Agent (IBA)

8	Proteins (Proteins, Gene)FDA Link 06/2022 - 04/2003
8	Antiviral Agents (Antivirals)IBA 01/2021 - 08/2003
6	CytokinesIBA 01/2022 - 09/2009
4	LigandsIBA 04/2020 - 02/2012
4	InterferonsIBA 01/2019 - 01/2006
3	Pharmaceutical PreparationsIBA 07/2022 - 07/2002
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 09/2009
3	RNA (Ribonucleic Acid)IBA 03/2020 - 07/2004
3	AntigensIBA 01/2019 - 05/2003
3	VaccinesIBA 01/2019 - 09/2005
3	EnzymesIBA 10/2003 - 07/2002
2	Immune Checkpoint InhibitorsIBA 07/2022 - 10/2019
2	Toll-Like Receptor 7IBA 01/2022 - 01/2021
2	Peptides (Polypeptides)IBA 01/2021 - 04/2006
2	Monoclonal AntibodiesIBA 01/2019 - 09/2011
2	N-Acetylneuraminic Acid (Sialic Acid)IBA 12/2016 - 12/2013
2	Rituximab (Mabthera)FDA Link 10/2015 - 09/2011
2	Ribavirin (Virazole)FDA LinkGeneric 07/2013 - 09/2004
2	Natural Killer Cell ReceptorsIBA 09/2009 - 02/2009
1	Chimeric Antigen ReceptorsIBA 07/2022
1	AntibodiesIBA 01/2022
1	Sirolimus (Rapamycin)FDA Link 01/2022
1	bafilomycin A1IBA 01/2022
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2022
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2022
1	To autoantigenIBA 01/2022
1	micaIBA 01/2022
1	TransferasesIBA 10/2021
1	Sialic Acid Binding Immunoglobulin-like LectinsIBA 10/2021
1	C-Reactive ProteinIBA 10/2020
1	KIR ReceptorsIBA 01/2019
1	HLA-Bw4 antigenIBA 01/2019
1	Norfloxacin FDA Link 01/2019
1	Programmed Cell Death 1 ReceptorIBA 01/2019
1	Natural Cytotoxicity Triggering Receptor 3IBA 01/2019
1	Interleukin-18 (Interleukin 18)IBA 12/2017
1	Transaminases (Aminotransferases)IBA 12/2016
1	Immunoglobulins (Immunoglobulin)IBA 12/2016
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 12/2016
1	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 12/2016
1	Protein Isoforms (Isoforms)IBA 10/2015
1	Attenuated VaccinesIBA 05/2014
1	Immunosuppressive Agents (Immunosuppressants)IBA 05/2014
1	Glycoproteins (Glycoprotein)IBA 12/2013
1	interleukin-21 (interleukin 21)IBA 04/2013
1	Interferon-alpha (Interferon Alfa)IBA 09/2012
1	STAT1 Transcription FactorIBA 01/2012
1	Messenger RNA (mRNA)IBA 01/2012
1	Immunoglobulin G (IgG)IBA 07/2011
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 03/2011
1	Interferon-gamma (Interferon, gamma)IBA 09/2009
1	NK Cell Lectin-Like Receptor Subfamily KIBA 09/2009
1	CryoglobulinsIBA 05/2007
1	Chloroquine (Aralen)FDA LinkGeneric 09/2005
1	CollagenIBA 01/2005
1	LeptinIBA 01/2005
1	Interferon alpha-2 (Roferon-A)FDA Link 09/2004
1	peginterferon alfa-2b (Pegintron)FDA Link 09/2004

Therapy/Procedure

8	Therapeutics 01/2021 - 08/2003
4	Liver Transplantation 06/2020 - 02/2009
2	Immunotherapy 09/2021 - 02/2012
1	Length of Stay 10/2020
1	Transplantation 05/2014
1	Cholecystectomy 09/2012
1	Highly Active Antiretroviral Therapy (HAART) 07/2004